<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2026-11.3.20</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-6189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Дозо- и времязависимое влияние двойного агониста рецепторов GIP/GLP-1 тирзепатида на эмоциональное переедание в модели электрической самостимуляции мозга у крыс</article-title><trans-title-group xml:lang="en"><trans-title>Dose- and time-dependent effects of the dual GIP/GLP-1 receptor agonist tirzepatide on emotional overeating in a rat model of intracranial self-stimulation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6231-445X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деданишвили</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Dedanishvili</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Деданишвили Николай Сергоевич – аспирант кафедры биологической химии.</p><p>194000, Санкт-Петербург, Литовская, 2</p></bio><bio xml:lang="en"><p>Nikolai S. Dedanishvili – postgraduate student of the Department of Biological Chemistry.</p><p>Litovskaya str., 2, St. Petersburg 194000</p></bio><email xlink:type="simple">votrenicolas@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4467-2269</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пюрвеев</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pyurveev</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пюрвеев Сарнг Саналович – кандидат медицинских наук, доцент кафедры патологической физиологии с курсом иммунопатологии; заведующий межкафедральной экспериментальной лаборатории кафедр патофизиологии, нормальной физиологии и медицинской биофизики.</p><p>194000, Санкт-Петербург, Литовская, 2</p></bio><bio xml:lang="en"><p>Sarng S. Pyurveev – Cand. Sc. (Med.), associate professor of the Department of Pathological Physiology with the course of Immunopathology; head of the Interdepartmental Experimental Laboratory of the Departments of Pathological Physiology, Normal Physiology and Medical Biophysics, St. Petersburg SPMU.</p><p>Litovskaya str., 2, St. Petersburg 194000</p></bio><email xlink:type="simple">dr.purveev@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7468-8563</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брус</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Brus</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Брус Татьяна Викторовна – доктор медицинских наук, доцент кафедры патологической физиологии с курсом иммунопатологии.</p><p>194000, Санкт-Петербург, Литовская, 2</p></bio><bio xml:lang="en"><p>Tatiana V. Brus – Dr. Sc. (Med.), associate professor of the Department of Pathological Physiology with the course of Immunopathology.</p><p>Litovskaya str., 2, St. Petersburg 194000</p></bio><email xlink:type="simple">bant.90@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8539-7128</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильев</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasiliev</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васильев Андрей Глебович – доктор медицинских наук, профессор, заведующий кафедрой патологической физиологии с курсом иммунопатологии.</p><p>194000, Санкт-Петербург, Литовская, 2</p></bio><bio xml:lang="en"><p>Andrei G. Vasiliev – Dr. Sc. (Med.), professor, head of the Department of Pathological Physiology with the course of Immunopathology.</p><p>Litovskaya str., 2, St. Petersburg 194000</p></bio><email xlink:type="simple">avas7@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2026</year></pub-date><volume>11</volume><issue>3</issue><fpage>162</fpage><lpage>170</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Деданишвили Н.С., Пюрвеев С.С., Брус Т.В., Васильев А.Г., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Деданишвили Н.С., Пюрвеев С.С., Брус Т.В., Васильев А.Г.</copyright-holder><copyright-holder xml:lang="en">Dedanishvili N.S., Pyurveev S.S., Brus T.V., Vasiliev A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/6189">https://www.actabiomedica.ru/jour/article/view/6189</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Несмотря на растущую распространенность эмоционального переедания и ожирения, остаются недостаточно изученными конкретные нейрогормональные механизмы в патогенезе данных патологических процессов. Инкретиновая система может служить важной терапевтической мишенью для коррекции этих расстройств пищевого поведения.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Изучить влияние двойного агониста рецепторов GIP и GLP-1 тирзепатида на показатели пищевого поведения при экспериментальном моделировании эмоционального переедания, вызванного электрической самостимуляцией мозга у крыс.</p></sec><sec><title>Методы</title><p>Методы. Эксперименты выполнены на крысах-самцах линии Вистар с имплантированными электродами в вентральную область покрышки. Тирзепатид вводили подкожно в дозах 0,05; 0,10 и 0,30 мг/кг курсом в течение 7 суток. Оценивали количество семян, потреблённых животными за 1 минуту, 30 минут, а также на 3-и и 7-е сутки после введения препарата.</p></sec><sec><title>Результаты</title><p>Результаты. Показано, что на 30-й минуте после введения тирзепатида статистически значимых изменений пищевой активности не выявлялось. На третьи сутки снижение потребления пищи отмечалось только при максимальной дозе (0,30 мг/кг). На седьмые сутки достоверное анорексигенное действие наблюдалось при дозах 0,10 и 0,30 мг/кг, что свидетельствует о дозои времязависимом характере эффекта.</p></sec><sec><title>Заключение</title><p>Заключение. Тирзепатид не оказывает выраженного острого влияния на пищевую активность в модели эмоционального переедания на 30-й минуте после введения. При повторном введении препарата выявляется дозои времязависимый анорексигенный эффект, проявляющийся снижением потребления пищи на 3-и и 7-е сутки эксперимента. Наиболее выраженное снижение пищевой активности наблюдается при дозах 0,10 и 0,30 мг/кг на 7-е сутки введения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Despite the increasing prevalence of emotional overeating and obesity, the specific neurohormonal mechanisms involved in the pathogenesis of these pathological processes remain poorly understood. The incretin system may serve as an important therapeutic target for the correction of these eating disorders.</p></sec><sec><title>Aim</title><p>Aim. To study the effects of the dual GIP/GLP-1 receptor agonist tirzepatide on feeding behavior parameters in a rat model of emotional overeating induced by intracranial self-stimulation (ICSS).</p></sec><sec><title>Methods</title><p>Methods. Experiments were performed on male Wistar rats with electrodes implanted in the ventral tegmental area. Tirzepatide was administered subcutaneously at doses of 0.05, 0.10, and 0.30 mg/kg for 7 days. Food intake (number of seeds consumed) was assessed at 1 minute, 30 minutes, and on days 3 and 7 after administration.</p></sec><sec><title>Results</title><p>Results. No statistically significant changes in feeding activity were observed 30 minutes after tirzepatide administration. On the third day, a decrease in food intake was observed only at the maximum dose (0.30 mg/kg). On the seventh day, a significant anorexigenic effect was observed at doses of 0.10 and 0.30 mg/kg, indicating a doseand time-dependent effect.</p></sec><sec><title>Conclusion</title><p>Conclusion. Tirzepatide does not exert a significant acute effect on feeding activity in the emotional overeating model at 30 minutes after administration. Repeated administration of the drug revealed a doseand time-dependent anorexigenic effect, manifested by a decrease in food intake on days 3 and 7 of the experiment. The most pronounced decrease in feeding activity was observed at doses of 0.10 and 0.30 mg/kg on day 7.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>тирзепатид</kwd><kwd>инкретин</kwd><kwd>GLP-1</kwd><kwd>GIP</kwd><kwd>эмоциональное переедание</kwd><kwd>самостимуляция мозга</kwd><kwd>VTA</kwd><kwd>пищевое поведение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tirzepatide</kwd><kwd>incretin</kwd><kwd>GLP-1</kwd><kwd>GIP</kwd><kwd>emotional overeating</kwd><kwd>brain stimulation</kwd><kwd>VTA</kwd><kwd>feeding behavior</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol. 2021; 11: 554961. doi: 10.3389/fphar.2020.554961</mixed-citation><mixed-citation xml:lang="en">Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol. 2021; 11: 554961. doi: 10.3389/fphar.2020.554961</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. 2020; 25(8): 1987. doi: 10.3390/molecules25081987</mixed-citation><mixed-citation xml:lang="en">Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. 2020; 25(8): 1987. doi: 10.3390/molecules25081987</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020; 5(17): e140532. doi: 10.1172/jci.insight.140532</mixed-citation><mixed-citation xml:lang="en">Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020; 5(17): e140532. doi: 10.1172/jci.insight.140532</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, et al. Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sci. 2024; 14(6): 617. doi: 10.3390/brainsci14060617</mixed-citation><mixed-citation xml:lang="en">Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, et al. Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sci. 2024; 14(6): 617. doi: 10.3390/brainsci14060617</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol Behav. 2019; 206: 232–42. doi: 10.1016/j.physbeh.2019.03.029</mixed-citation><mixed-citation xml:lang="en">Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol Behav. 2019; 206: 232–42. doi: 10.1016/j.physbeh.2019.03.029</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Razzaki TS, Weiner A, Shukla AP. Tirzepatide: does the evidence to date show potential for the treatment of early stage type 2 diabetes? Ther Clin Risk Manag. 2022; 18: 955–64. doi: 10.2147/TCRM.S328056</mixed-citation><mixed-citation xml:lang="en">Razzaki TS, Weiner A, Shukla AP. Tirzepatide: does the evidence to date show potential for the treatment of early stage type 2 diabetes? Ther Clin Risk Manag. 2022; 18: 955–64. doi: 10.2147/TCRM.S328056</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA. Dual GIP and GLP1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021; 106(2): 388-396. doi: 10.1210/clinem/dgaa863</mixed-citation><mixed-citation xml:lang="en">Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA. Dual GIP and GLP1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021; 106(2): 388-396. doi: 10.1210/clinem/dgaa863</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020; 31(6): 410–21. doi: 10.1016/j.tem.2020.02.006</mixed-citation><mixed-citation xml:lang="en">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020; 31(6): 410–21. doi: 10.1016/j.tem.2020.02.006</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sizov VV, Lebedev AA, Pyurveev SS, et al. A method for training rats to electrical self-stimulation in response to raising the head using a telemetry apparatus to record extracellular dopamine levels. Neurosci Behav Physiol. 2024; 54(1): 52–60. doi: 10.1007/s11055-024-01568-z</mixed-citation><mixed-citation xml:lang="en">Sizov VV, Lebedev AA, Pyurveev SS, et al. A method for training rats to electrical self-stimulation in response to raising the head using a telemetry apparatus to record extracellular dopamine levels. Neurosci Behav Physiol. 2024; 54(1): 52–60. doi: 10.1007/s11055-024-01568-z</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lebedev AA, Bessolova YN, Efimov NS, et al. Role of orexin peptide system in emotional overeating induced by brain reward stimulation in fed rats. Res Results Pharmacol. 2020; 6(1): 81–91. doi: 10.3897/rrpharmacology.6.52180</mixed-citation><mixed-citation xml:lang="en">Lebedev AA, Bessolova YN, Efimov NS, et al. Role of orexin peptide system in emotional overeating induced by brain reward stimulation in fed rats. Res Results Pharmacol. 2020; 6(1): 81–91. doi: 10.3897/rrpharmacology.6.52180</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–216. doi: 10.1056/NEJMoa2206038</mixed-citation><mixed-citation xml:lang="en">Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–216. doi: 10.1056/NEJMoa2206038</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398(10295): 143–155. doi: 10.1016/S0140-6736(21)01324-6</mixed-citation><mixed-citation xml:lang="en">Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398(10295): 143–155. doi: 10.1016/S0140-6736(21)01324-6</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124(10): 4473–4488. doi: 10.1172/JCI75276</mixed-citation><mixed-citation xml:lang="en">Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124(10): 4473–4488. doi: 10.1172/JCI75276</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control food intake. Endocrinology. 2012; 153(2): 647–658. doi: 10.1210/en.2011-1443</mixed-citation><mixed-citation xml:lang="en">Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control food intake. Endocrinology. 2012; 153(2): 647–658. doi: 10.1210/en.2011-1443</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bae JH, Choi HJ, Cho KIK, Kim LK, Kwon JS, Cho YM. Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus. Diabetes Metab J. 2020; 44(2): 248–259. doi: 10.4093/dmj.2019.0018</mixed-citation><mixed-citation xml:lang="en">Bae JH, Choi HJ, Cho KIK, Kim LK, Kwon JS, Cho YM. Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus. Diabetes Metab J. 2020; 44(2): 248–259. doi: 10.4093/dmj.2019.0018</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Choi W, Nho YH, Qiu L, Chang A, Campos G, Seilheimer RL, et al. Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide. Nat Med. 2025; 31(12): 4038–4043. doi: 10.1038/s41591-025-04035-5</mixed-citation><mixed-citation xml:lang="en">Choi W, Nho YH, Qiu L, Chang A, Campos G, Seilheimer RL, et al. Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide. Nat Med. 2025; 31(12): 4038–4043. doi: 10.1038/s41591-025-04035-5</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022; 137: 105667. doi: 10.1016/j.psyneuen.2022.105667</mixed-citation><mixed-citation xml:lang="en">van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022; 137: 105667. doi: 10.1016/j.psyneuen.2022.105667</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020; 31(6): 410–421. doi: 10.1016/j.tem.2020.02.006</mixed-citation><mixed-citation xml:lang="en">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020; 31(6): 410–421. doi: 10.1016/j.tem.2020.02.006</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503–515. doi: 10.1056/NEJMoa2107519</mixed-citation><mixed-citation xml:lang="en">Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503–515. doi: 10.1056/NEJMoa2107519</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025; 31(9): 3141–50. doi: 10.1038/s41591-025-03774-9</mixed-citation><mixed-citation xml:lang="en">Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025; 31(9): 3141–50. doi: 10.1038/s41591-025-03774-9</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fortin SM, Roitman MF. Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core. Physiol Behav. 2017; 176: 17–25. doi: 10.1016/j.physbeh.2017.03.019</mixed-citation><mixed-citation xml:lang="en">Fortin SM, Roitman MF. Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core. Physiol Behav. 2017; 176: 17–25. doi: 10.1016/j.physbeh.2017.03.019</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015; 21(1): 27–36. doi: 10.1038/nm.3761</mixed-citation><mixed-citation xml:lang="en">Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015; 21(1): 27–36. doi: 10.1038/nm.3761</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Galindo RJ, Cheng AYY, Longuet C, Ai M, Coskun T, Malik R, et al. Insights into the mechanism of action of tirzepatide: a narrative review. Diabetes Ther. 2026; 17(1): 19–40. doi: 10.1007/s13300-025-01804-w</mixed-citation><mixed-citation xml:lang="en">Galindo RJ, Cheng AYY, Longuet C, Ai M, Coskun T, Malik R, et al. Insights into the mechanism of action of tirzepatide: a narrative review. Diabetes Ther. 2026; 17(1): 19–40. doi: 10.1007/s13300-025-01804-w</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3): 205–216. doi: 10.1056/NEJMoa2206038</mixed-citation><mixed-citation xml:lang="en">Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3): 205–216. doi: 10.1056/NEJMoa2206038</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021; 20(1): 225. doi: 10.1186/s12933-021-01412-5</mixed-citation><mixed-citation xml:lang="en">Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021; 20(1): 225. doi: 10.1186/s12933-021-01412-5</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022; 27(13): 4315. doi: 10.3390/molecules27134315</mixed-citation><mixed-citation xml:lang="en">Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022; 27(13): 4315. doi: 10.3390/molecules27134315</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
